Htg Molecular Diagnostics, Inc HTGM
We take great care to ensure that the data presented and summarized in this overview for HTG MOLECULAR DIAGNOSTICS, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HTGM
View allLatest Institutional Activity in HTGM
Top Purchases
Top Sells
About HTGM
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Insider Transactions at HTGM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2023
|
Stephen Barat Senior VP of Therapeutics |
SELL
Open market or private sale
|
Direct |
888
-67.84%
|
$0
$0.8 P/Share
|
|
Mar 31
2023
|
Stephen Barat Senior VP of Therapeutics |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-3.82%
|
$104
$2.7 P/Share
|
|
Dec 09
2022
|
Laura Lee Godlewski SVP Finance & Administration |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+16.94%
|
$0
$0.42 P/Share
|
|
Dec 09
2022
|
Shaun D Mc Means SVP, Finance & Admin. & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+8.64%
|
$0
$0.42 P/Share
|
|
Dec 09
2022
|
John L Lubniewski President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+6.61%
|
$0
$0.42 P/Share
|
|
Dec 09
2022
|
Byron Lawson SVP/Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+14.22%
|
$0
$0.42 P/Share
|
|
Jun 30
2022
|
John L Lubniewski President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
61
-0.46%
|
$61
$1.03 P/Share
|
|
Jun 30
2022
|
Shaun D Mc Means SVP, Finance & Admin. & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
29
-0.3%
|
$29
$1.03 P/Share
|
|
Jun 30
2022
|
Byron Lawson SVP/Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23
-0.45%
|
$23
$1.03 P/Share
|
|
Jun 10
2022
|
Byron Lawson SVP/Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+16.51%
|
$0
$0.48 P/Share
|
|
Jun 10
2022
|
John L Lubniewski President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+7.05%
|
$0
$0.48 P/Share
|
|
Jun 10
2022
|
Shaun D Mc Means SVP, Finance & Admin. & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+9.43%
|
$0
$0.48 P/Share
|
|
Jun 10
2022
|
Laura Lee Godlewski SVP Finance & Administration |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+20.39%
|
$0
$0.48 P/Share
|
|
Mar 31
2022
|
John L Lubniewski President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
62
-0.51%
|
$62
$1.39 P/Share
|
|
Mar 31
2022
|
Shaun D Mc Means SVP, Finance & Admin. & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.36%
|
$31
$1.39 P/Share
|
|
Mar 31
2022
|
Byron Lawson SVP/Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23
-0.56%
|
$23
$1.39 P/Share
|
|
Dec 31
2021
|
John L Lubniewski President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
62
-0.5%
|
$310
$5.42 P/Share
|
|
Dec 31
2021
|
Shaun D Mc Means SVP, Finance & Admin. & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.36%
|
$155
$5.42 P/Share
|
|
Dec 31
2021
|
Byron Lawson SVP/Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24
-0.58%
|
$120
$5.42 P/Share
|
|
Dec 10
2021
|
John L Lubniewski President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+7.51%
|
$3,000
$3.56 P/Share
|